{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:36:07Z","timestamp":1791041767693,"version":"4.1.0"},"reference-count":26,"publisher":"The Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Context: There is currently no medical therapy for Cushing\u2019s disease that targets the pituitary adenoma. Availability of such a medical therapy would be a valuable therapeutic option for the management of this disorder.<\/jats:p>\n                  <jats:p>Objective: Our objective was to evaluate the short-term efficacy of the novel multireceptor ligand somatostatin analog pasireotide in patients with de novo, persistent, or recurrent Cushing\u2019s disease.<\/jats:p>\n                  <jats:p>Design: We conducted a phase II, proof-of-concept, open-label, single-arm, 15-d multicenter study.<\/jats:p>\n                  <jats:p>Patients: Thirty-nine patients with either de novo Cushing\u2019s disease who were candidates for pituitary surgery or with persistent or recurrent Cushing\u2019s disease after surgery without having received prior pituitary irradiation.<\/jats:p>\n                  <jats:p>Intervention: Patients self-administered sc pasireotide 600 \u03bcg twice daily for 15 d.<\/jats:p>\n                  <jats:p>Main Outcome Measure: Normalization of urinary free cortisol (UFC) levels after 15 d treatment was the main outcome measure.<\/jats:p>\n                  <jats:p>Results: Of the 29 patients in the primary efficacy analysis, 22 (76%) showed a reduction in UFC levels, of whom five (17%) had normal UFC levels (responders), after 15 d of treatment with pasireotide. Serum cortisol levels and plasma ACTH levels were also reduced. Steady-state plasma concentrations of pasireotide were achieved within 5 d of treatment. Responders appeared to have higher pasireotide exposure than nonresponders.<\/jats:p>\n                  <jats:p>Conclusions: Pasireotide produced a decrease in UFC levels in 76% of patients with Cushing\u2019s disease during the treatment period of 15 d, with direct effects on ACTH release. These results suggest that pasireotide holds promise as an effective medical treatment for this disorder.<\/jats:p>","DOI":"10.1210\/jc.2008-1008","type":"journal-article","created":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T22:13:39Z","timestamp":1225232019000},"page":"115-122","source":"Crossref","is-referenced-by-count":231,"title":["Treatment of Pituitary-Dependent Cushing\u2019s Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial"],"prefix":"10.1210","volume":"94","author":[{"given":"M.","family":"Boscaro","sequence":"first","affiliation":[{"name":"Division of Endocrinology (M.B.), Polytechnic University of Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. H.","family":"Ludlam","sequence":"additional","affiliation":[{"name":"Seattle Pituitary Center (W.H.L.), Swedish Neurosciences Institute, Seattle, Washington 98122"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Regional Centre for Endocrinology and Diabetes (B.A.), Royal Victoria Hospital, Belfast BT12 6BA, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E.","family":"Glusman","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development (J.E.G., C.H.D., K.H., Y.W.), Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07932"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Petersenn","sequence":"additional","affiliation":[{"name":"Division of Endocrinology (S.P.), Medical Center, University of Essen, 45122 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reincke","sequence":"additional","affiliation":[{"name":"Medizinische Klinik Innenstadt Klinikum der Universita\u0308t Mu\u0308nchen (M.R.), 80336 Mu\u0308nchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Snyder","sequence":"additional","affiliation":[{"name":"University of Pennsylvania (P.S.), Philadelphia, Pennsylvania 19104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tabarin","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie (A.T.), Centre Hospitalier Universitaire Bordeaux, Haut Le\u0301ve\u0302que, 33075 Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. M. K.","family":"Biller","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital (B.M.K.B.), Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Findling","sequence":"additional","affiliation":[{"name":"Midwest Endocrinology Associates (J.F.), Milwaukee, Wisconsin 53215"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Melmed","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Pituitary Center (S.M.), Los Angeles, California 90048"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. H.","family":"Darby","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development (J.E.G., C.H.D., K.H., Y.W.), Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07932"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hu","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development (J.E.G., C.H.D., K.H., Y.W.), Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07932"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development (J.E.G., C.H.D., K.H., Y.W.), Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07932"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. U.","family":"Freda","sequence":"additional","affiliation":[{"name":"Department of Medicine (P.U.F.), Division of Endocrinology, Columbia University, New York, New York 10027"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. B.","family":"Grossman","sequence":"additional","affiliation":[{"name":"Department of Endocrinology (A.B.G.), St. Bartholomew\u2019s Hospital, EC1M 6BQ London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. A.","family":"Frohman","sequence":"additional","affiliation":[{"name":"Department of Medicine (L.A.F.), Section of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, Illinois 60637"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bertherat","sequence":"additional","affiliation":[{"name":"Center for Rare Adrenal Diseases (J.B.), Department of Endocrinology, Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale Unit 567, Paris-Descartes University, Cochin Hospital, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071613565998700_R1","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of ACTH-dependent Cushing\u2019s syndrome: a consensus statement.","volume":"93","author":"Biller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613565998700_R2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2265.2006.02610.x","article-title":"PPAR-\u03b3 expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-\u03b3 receptor.","volume":"65","author":"Emery","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613565998700_R3","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/nm784","article-title":"Functional PPAR-\u03b3 receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas.","volume":"8","author":"Heaney","year":"2002","journal-title":"Nat Med"},{"key":"2020071613565998700_R4","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1172\/JCI200316575","article-title":"PPAR-\u03b3 receptor ligands: novel therapy for pituitary adenomas.","volume":"111","author":"Heaney","year":"2003","journal-title":"J Clin Invest"},{"key":"2020071613565998700_R5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2265.2006.02501.x","article-title":"The PPAR-\u03b3 activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson\u2019s syndrome.","volume":"64","author":"Mullan","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613565998700_R6","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1210\/jc.2006-2005","article-title":"Ineffectiveness of rosiglitazone therapy in Nelson\u2019s syndrome.","volume":"92","author":"Munir","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613565998700_R7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2265.2006.02452.x","article-title":"Effect of protracted treatment with rosiglitazone, a PPAR\u03b3 agonist, in patients with Cushing\u2019s disease.","volume":"64","author":"Pecori","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613565998700_R8","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/en.2006-0414","article-title":"Retinoic acid as a novel medical therapy for Cushing\u2019s disease in dogs.","volume":"147","author":"Castillo","year":"2006","journal-title":"Endocrinology"},{"key":"2020071613565998700_R9","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","article-title":"Dopamine receptor expression and function in corticotroph pituitary tumors.","volume":"89","author":"Pivonello","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613565998700_R10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF03349555","article-title":"Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion.","volume":"13","author":"Ambrosi","year":"1990","journal-title":"J Endocrinol Invest"},{"key":"2020071613565998700_R11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2265.1990.tb00867.x","article-title":"Treatment of Cushing\u2019s syndrome with the long-acting somatostatin analogue SMS 201-995 (sandostatin).","volume":"32","author":"Invitti","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613565998700_R12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1530\/acta.0.1200760","article-title":"The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson\u2019s syndrome and Cushing\u2019s disease.","volume":"120","author":"Lamberts","year":"1989","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071613565998700_R13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"2020071613565998700_R14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","article-title":"Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors","volume":"80","author":"Schmid","year":"2004","journal-title":"Neuroendocrinology"},{"key":"2020071613565998700_R15","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2006-1245","article-title":"The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.","volume":"91","author":"Batista","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613565998700_R16","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1210\/jc.2003-031319","article-title":"The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion.","volume":"89","author":"Murray","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613565998700_R17","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1152\/ajpendo.00004.2005","article-title":"Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumour cells","volume":"289","author":"Van Der Hoek","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020071613565998700_R18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","article-title":"The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.","volume":"152","author":"Hofland","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"2020071613565998700_R19","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1530\/eje.1.01998","article-title":"Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats","volume":"153","author":"Silva","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"2020071613565998700_R20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM230): development, mechanism of action and potential applications.","volume":"286","author":"Schmid","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"2020071613565998700_R21","first-page":"196","article-title":"The clinical evaluation of chemotherapeutic agents in cancer","author":"Karnofsky","year":"1949","journal-title":"In: MacLeod CM, ed. Evaluation of chemotherapeutic agents. New York: Columbia University Press;"},{"key":"2020071613565998700_R22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials.","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"2020071613565998700_R23","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJM199503233321207","article-title":"Cushing\u2019s syndrome.","volume":"332","author":"Orth","year":"1995","journal-title":"N Engl J Med"},{"key":"2020071613565998700_R24","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1210\/jc.2003-030871","article-title":"Diagnosis and complications of Cushing\u2019s syndrome: a consensus statement.","volume":"88","author":"Arnaldi","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613565998700_R25","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1136\/bmj.291.6507.1453","article-title":"Five cases of cyclical Cushing\u2019s syndrome.","volume":"291","author":"Atkinson","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2020071613565998700_R26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1586\/17446651.2.2.129","article-title":"Octreotide for acromegaly.","volume":"2","author":"Cozzi","year":"2007","journal-title":"Expert Rev Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/1\/115\/9057431\/jcem0115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/1\/115\/9057431\/jcem0115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T21:01:28Z","timestamp":1594933288000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/94\/1\/115\/2597849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2008-1008","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1157701.617915","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}